Back to News
Market Impact: 0.2
Biofrontera Submits Ameluz SNDA For Expanded Actinic Keratosis Use
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Biofrontera Inc. (BFRI) submitted a supplemental New Drug Application to the U.S. FDA seeking to expand the approved use of Ameluz with photodynamic therapy for actinic keratoses. The article reports the application submission, not an FDA decision.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
BFRI0.45
More News
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- SpaceX to buy key spectrum that could help Starlink Mobile become major US cell carrier
- Why is the Chinese stock market missing the AI rally
- ‘Piece by piece’: Trump administration vows to dismantle the International Criminal Court with sweeping new sanctions
- Why is T-Mobile stock tumbling today?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Research Tools for Pension Funds and Allocators
- AllMind's Data Standardization Methodology: Our Approach to Fundamentals